Zomedica Pharmaceuticals Corp (ZOM)
$0.20
0.01 (3.94%)
ZOM Stock Quote Delayed 30 Minutes
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning!
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
191.09M
PE Ratio
-10.26
EPS
-0.019
Volume (Avg. Vol.)
7.24M
Day's Range
$0.19 - $0.20
52-Week Range
$0.18 - $0.50
Dividend & Yield
N/A (N/A)
ZOM Stock Predictions, Articles, and Zomedica Pharmaceuticals Corp News
It’s Going to Take a Lot to Get Zomedica Stock Out of the Doghouse
ZOM stockholders are likely to grow increasingly frustrated with management's misplaced optimism and the lack of Truforma sales.
Will the PulseVet Acquisition Continue to Deliver Sales for Zomedica?
Zomedica Corp. (NYSEAMERICAN:ZOM) finally has a catalyst that could be a game-changer. It has reported $4.1 million in revenue for full-year 2021. This is big....
Zomedica’s Shareholders Should Be Worried About the Outlook of ZOM Stock
ZOM stock has been a toxic asset for nearly a year, and Zomedica isn't giving investors much to get enthused about.
Zomedica Stock Should Have Popped on This Latest Acquisition, so Beware
Although ZOM stock has some exciting news to undergird its price tag, that hardly anything has changed is worrying.
There’s a Reason to Consider Buying Zomedica, and It’s a Real Shocker
ZOM stock is far from a market darling, but an underreported acquisition could breathe new life into Zomedia's struggling business.
Zomedica Remains a Speculative Play in the Veterinary Field
The dismal run of ZOM Stock likely to continue for the foreseeable future, until it meaningfully improves its top and bottom-line numbers.
Penny Stocks to Watch: What’s Going on With ZOM, DARE, PSFE, EFOI and AUUD Today?
Penny stocks are still a hot topic among retail traders and we're covering some of the top ones to watch Wednesday that are on the move.
Zomedica Stock Looks Tempting Here, But There’s Likely More Downside
Early in 2021, ZOM stock was part of the meme stock trade. But recent catalysts suggest it may be time to view it as an investment.
Zomedica Is Languishing Today, but Keep an Eye on This Risky Play
It's a risky play no doubt, but ZOM stock stands to get out of its current rut as a key temporary issue subsides.
Pet Stocks Alert: What Is Going on With PETZ and ZOM Stocks Today?
Speculative pet stocks TDH Holdings and Zomedica are jumping higher in morning trading but investors should be skeptical of the moves.
Stay Away From Zomedica for These 3 Key Reasons
ZOM stock had its best days in early 2021, but now its weak financial performance fully justifies its price weakness.
Zomedica Management Finally Delivers Some Good News
Zomedica's acquisition is precisely what was needed to get ZOM stock out of its lethargy. Long-term, it could be a game-changer. Here’s why.
Zomedica Stock Will Need More Than a Change in Management to Bounce Back
While a C-suite scenery change might be good for Zomedica, the shift may not provide a similar outcome for ZOM stock.
New CEO and Acquisition Could Breathe New Life Into Zomedica
A turnaround in ZOM stock may happen sooner rather than later as Zomedica undergoes an executive-level change and builds out its business.
Zomedica Has Potential, but It’s Far Too Expensive for Now
ZOM stock can be a pet care industry leader, but it needs to make significant improvements before becoming a solid long-term play.
The Challenges for Zomedica Continue, But It Still Has Huge Potential
Cautious investors may want to hold off, as no matter what direction it goes (higher or lower), it'll do so in a big way. But if you can stomach the risk, and have patience to wait out its current troubles, ZOM stock may be an opportunity.
